Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US-9718863-B2 · Aug 1, 2017 · US
Chimpanzee adenoviral vector-based filovirus vaccines
US10584355B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10584355-B2 |
| Application number | US-201615339225-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2016 |
| Priority date | Apr 16, 2010 |
| Publication date | Mar 10, 2020 |
| Grant date | Mar 10, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated nucleic acid molecule, wherein the isolated nucleic acid molecule comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. 2. The isolated nucleic acid molecule of claim 1 , comprising an expression cassette comprising a CMV promoter operably linked to a polynucleotide sequence encoding a filovirus antigenic protein. 3. The isolated nucleic acid molecule of claim 1 , which comprises a sequence identical to SEQ ID NO:1. 4. The isolated nucleic acid molecule of claim 1 , which comprises a sequence identical to SEQ ID NO:2. 5. The isolated nucleic acid molecule of claim 1 , which comprises a sequence identical to SEQ ID NO:3. 6. The isolated nucleic acid molecule of claim 3 , further comprising a promoter operably linked to said nucleic acid molecule. 7. The isolated nucleic acid molecule of claim 4 , further comprising a promoter operably linked to said nucleic acid molecule. 8. The isolated nucleic acid molecule of claim 5 , further comprising a promoter operably linked to said nucleic acid molecule. 9. A composition, comprising: the isolated nucleic acid molecule of claim 3 ; and a pharmaceutically acceptable carrier. 10. A composition, comprising: the isolated nucleic acid molecule of claim 4 ; and a pharmaceutically acceptable carrier. 11. A composition, comprising: the isolated nucleic acid molecule of claim 5 ; and a pharmaceutically acceptable carrier. 12. The isolated nucleic acid molecule of claim 6 , wherein the promoter is a CMV promoter. 13. The isolated nucleic acid molecule of claim 7 , wherein the promoter is a CMV promoter. 14. The isolated nucleic acid molecule of claim 8 , wherein the promoter is a CMV promoter. 15. A composition, comprising: the isolated nucleic acid of claim 1 contained in a viral particle and a pharmaceutically acceptable carrier. 16. A composition, comprising: the isolated nucleic acid molecule of claim 1 ; and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
viral genome or elements thereof as genetic vector · CPC title
expressing foreign proteins · CPC title
characterised by the dose, timing or administration schedule · CPC title
avirulent or attenuated · CPC title
- A61K39/12Primary
Viral antigens · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10584355B2 cover?
- This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
- Who is the assignee on this patent?
- Us Gov Health & Human Services, Glaxosmithkline Biologicals Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).